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Understanding gene-environment interactions in the pathogenesis of schizophrenia
remains a major research challenge. Matrix metalloproteinase-9 (MMP-9) has been
previously implicated in the pathophysiology of schizophrenia. In the present study,
adolescent Mmp-9 heterozygous mice, with a genetically lower level of MMP-9, were
subjected to resident-intruder psychosocial stress for 3 weeks and then examined
in behavioral tests that evaluated cognitive deficits and positive- and negative-like
symptoms of schizophrenia. Cognitive and positive symptoms in unstressed Mmp-9
heterozygous mice were unaffected by stress exposure, whereas negative symptoms
were manifested only after stress exposure. Interestingly, negative symptoms were
ameliorated by treatment with the antipsychotic drug clozapine. We describe a novel
gene × environment interaction mouse model of schizophrenia. Lower MMP-9 levels in
the brain might be a risk factor for schizophrenia that, in combination with environmental
factors (e.g., psychosocial stress), may evoke schizophrenia-like symptoms that are
sensitive to antipsychotic treatment.
Keywords: gene × environment (G×E) interaction, schizophrenia, negative symptoms, clozapine, antipsychotic,
MMP-9
INTRODUCTION
Schizophrenia is a neuropsychiatric disorder that affects approximately 0.5% of the human
population (Saha et al., 2005). The disease is characterized by the heterogeneous display of
positive symptoms (e.g., hallucinations, delusions, and thought disorder), negative symptoms
(e.g., avolition, restricted affect, poverty of speech, and social withdrawal), and cognitive deficits
(e.g., working memory deficits, executive dysfunction, and attentional impairments). The onset
of schizophrenia typically occurs during early adulthood and is usually associated with lifelong
disability (Lewis and Lieberman, 2000; Cirulli et al., 2009; Schmitt et al., 2014; Flores et al., 2016).
Although multiple genes have been implicated in the etiology of schizophrenia (McGuffin et al.,
2003; Hosak, 2013), no single genetic alteration has been able to satisfactorily explain all of its
complex symptoms (Gottesman and Shields, 1967; Sanders et al., 2008). Thus, environmental
factors have been suggested to interact with genetic liability to cause this disease (Tsuang,
2000; Mackay-Sim et al., 2003; McGrath et al., 2004; Owen et al., 2005; van Os et al., 2010;
Hosák and Hosakova, 2015).
In stimulated neurons, matrix metalloproteinase-9 (MMP-9) is secreted from dendritic spines
that harbor excitatory synapses (Wilczynski et al., 2008; Szepesi et al., 2014). MMP-9 has been
shown to be involved in N-methyl-D-aspartate (NMDA) signaling and functional and structural
synaptic plasticity (Huntley, 2012; Vafadari et al., 2016). These phenomena have been implicated in
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the pathophysiology of schizophrenia (Olney et al., 1999; Anand
et al., 2000; du Bois and Huang, 2007; Penzes et al., 2011; Moyer
et al., 2015). Recent studies of MMP-9 gene polymorphisms
and MMP-9 mRNA and protein levels have implicated MMP-9
in schizophrenia patients (Rybakowski et al., 2009; Lepeta and
Kaczmarek, 2015; Lepeta et al., 2017). Mmp-9 knockout mice
have also been shown to exhibit alterations of emotional and
cognitive behaviors (Mizoguchi et al., 2010).
To investigate the possible role of environmental factors that
act in concert with Mmp-9-dependent genetic predisposition
in schizophrenia, we studied Mmp-9 heterozygous knockout
mice with low MMP-9 activity. The mice were subjected to
psychosocial stress in a modified resident-intruder paradigm
(Adamcio et al., 2009) and then tested in various behavioral
paradigms to analyze cognitive deficits and positive- and
negative-like symptoms of schizophrenia. Wild type (wt)
mice were compared with Mmp-9 heterozygotes, and stressed
mice were compared with non-stressed mice. The stress
procedure that was employed herein is considered to mimic
at-risk disease conditions, such as social stress (e.g., urbanicity
and social threat perception; Lewis et al., 1992; Kelly et al., 2010;
Lederbogen et al., 2013; Haddad et al., 2015), bullying (Trotta
et al., 2013), and adolescent trauma (Morgan et al., 2007).
MATERIALS AND METHODS
Animals
Mice were obtained from an in-house breeding facility at
the Animal House at Nencki Institute. The experiments
were conducted in 2-month-old, gender-matched Mmp-9
heterozygous knockout mice on a C57Bl/6J background and wt
C57Bl/6J littermates. For the induction of psychosocial stress,
gender-matched adult FVB mice were used as the aggressor
strain. Food and water were provided ad libitum. Temperature
was maintained at 21–23◦C with 50%–60% relative humidity and
a 12/12 h light/dark cycle (lights on 7 AM–7 PM). All of the
procedures were performed by experimenters who were blind to
genotype and were in accordance with the Animal Protection Act
in Poland (Directive 2010/63/EU) and approved by the 1st Local
Ethical Committee on Animal Experimentation of the Faculty
of Biology, Warsaw University (permission no. 148/2016 and
507/2018). The total number of mice that were used for the
behavioral experiments after stress exposure was 41 (n = 8 control
wt, n = 12 control Mmp-9 heterozygotes, n = 9 stressed wt,
n = 12 stressed Mmp-9 heterozygotes). For the analysis of the
effect of clozapine, the total number of mice was 22 (n = 5 control
wt, n = 6 control Mmp-9 heterozygotes, n = 5 stressed wt,
n = 6 stressed Mmp-9 heterozygotes). The vehicle control
groups comprised 12 mice (n = 6 stressed wt, n = 6 stressed
Mmp-9 heterozygotes). Initially, the enzymatic activity of
MMP-9 in brain extracts from heterozygous mice was assessed.
The analysis revealed that MMP-9 levels in heterozygous mice
were two-fold lower than in wt mice (Figure 1F).
Psychosocial Stress
This procedure was adapted from a previous study (Adamcio
et al., 2009). Individually housed wt mice and Mmp-9
heterozygotes were introduced as intruders in the cage of
gender-matched aggressor FVB mice. They were allowed to
interact until the first attack by the aggressor FVB mouse.
Mmp-9 heterozygotes and wt mice were then placed under
a perforated metal-cup cage to limit physical interaction for
1 h. To prevent habituation, a Latin-square distribution of
the intruder and aggressor mice was used (Pryce and Fuchs,
2016). Briefly, experimental mice were introduced to different
aggressors everyday that followed a circular combination pattern.
The procedure lasted 21 days.
Behavioral Tests
The behavioral tests were performed to assess cognitive deficits
and positive and negative symptoms of schizophrenia. At
the end of the behavioral tests, the mice were sacrificed for
subsequent molecular analysis. In another series of experiments,
after the mice were subjected to stress, they were treated
with the atypical antipsychotic drug clozapine. One week after
clozapine administration, the mice underwent behavioral testing.
All movements were recorded with an overhead video camera
and analyzed using Noldus Ethovision XT software for all of
the behavioral tests, with the exception of the tail suspension
test and social interaction test, which were video recorded for
later analysis.
Analysis of Positive-Like Symptoms
MK-801 (dizocilpine maleate) is an NMDA receptor
antagonist that induces pro-hallucinogenic effects in humans
and hyperlocomotion in rodents (van den Buuse, 2010).
MK-801-induced hyperlocomotion is employed to model and
analyze schizophrenia-like behavior in rodents (Young et al.,
2010; Jones et al., 2011). Mmp-9 heterozygous and wt mice were
placed in an open field apparatus (40 cm × 40 cm) and allowed
free exploration for the first 30 min. The mice were then given
an intraperitoneal injection of physiological saline and returned
to the open field for 1 h. Afterward, the mice received MK-801
(0.25 mg/kg, Sigma) and were reintroduced to the open field
and allowed free exploration for 1 h. All movements were video
recorded and post analyzed with Ethovision XT software.
Analysis of Cognitive Deficits
The novel object recognition test is used to assess cognitive
abilities in mice. The protocol that was used in the present study
was adapted from a previous study (Vogel-Ciernia and Wood,
2014). The novel object recognition test and its variations have
been used to assess cognitive symptoms in rodent models of
schizophrenia (Jones et al., 2011; Stuchlik and Sumiyoshi, 2014;
Grayson et al., 2015). The mice were placed in an open field
apparatus with ∼50 lux illumination and allowed free exploration
for 10 min. Afterward, two similar objects were placed on the
same axis near two corners of the apparatus. The mice were
allowed to explore these two objects for 5 min and then they
were returned to their home cage for 1 h. At the end of this
period, one of the objects was moved to a new location in the
apparatus (i.e., to the diagonal corner that was opposite to the
other object). The mice were reintroduced to the apparatus and
allowed to explore the objects for 5 min. All movements were
video recorded and post analyzed with Ethovision XT software.
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FIGURE 1 | (A) Schematic diagram of the experiment. (B) Tail suspension test. Stressed Mmp-9 heterozygous mice had a longer duration of immobility [individual
t-test, p < 0.05; two-way analysis of variance (ANOVA), F(1,37) = 7.008, p < 0.05] compared with their non-stressed counterparts and stressed wt mice. (C) Social
interaction test. The time spent interacting with unfamiliar mice decreased in stressed heterozygous mice (individual t-test, p < 0.05; two-way ANOVA,
F(1,37) = 8.9555, p < 0.05) compared with their non-stressed counterparts and stressed wt mice. (D) Novel object recognition test. Mmp-9 heterozygous mice spent
less time with the novel object (individual t-test, p < 0.05) compared with wt mice. (E) Treatment with MK-801 increases the distance traveled in the open field in
heterozygous mice and stressed wt mice (individual t-test, p < 0.05; two-way ANOVA, F(1,37) = 14.61, p < 0.005) compared with non-stressed wt mice. (F) Gel
zymography and relative densitometric plot of matrix metalloproteinase-9 (MMP-9) activity normalized to MMP-2 activity. MMP-9 activity significantly decreased
(individual U-test, p < 0.05; two-way ANOVA, F(1,8) = 13.9, p < 0.05) after stress exposure compared with the other groups. wt, wt mice; Het, Mmp-9 heterozygous
mice. ∗p < 0.05, ∗∗p < 0.01.
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Analysis of Negative-Like Symptoms
The tail suspension test was designed to assess the effect of
stress in mice, the results of which are considered to measure
behavioral despair and the lack of motivation, characteristics of
negative symptoms of schizophrenia (Porsolt et al., 1993). The
mice were suspended by their tail for 5 min from the edge of a
box with a white background. The distance between the mouse’s
nose and the ground was 20 cm.
The social interaction test was developed to analyze
anxiety-like behavior and traits of social avoidance in mice
(Defensor et al., 2011). Social withdrawal is also a characteristic
negative symptom of schizophrenia (Porsolt et al., 1993).
Experimental mice and gender-matched novel wt mice
(2–3 months old) of the same strain (C57Bl/6J) were introduced
to a testing cage. They were allowed to interact with each other
for 10 min. The total duration of interaction (e.g., nose to nose,
nose to head, nose to ano-genital region) was analyzed manually.
Clozapine Treatment
Clozapine is an atypical antipsychotic that is one of the
most potent drugs to treat schizophrenia (Asenjo Lobos
et al., 2010). The stock solution of clozapine was prepared
in 0.1 N HCl and diluted in phosphate-buffered saline. All
mice groups were treated with 5 mg/kg clozapine (Sigma)
intraperitoneally for 10 days. Control mice received only vehicle.
After administration, the mice had a resting period followed by
behavioral tests as described in Figure 2A.
Gelatin Gel Zymography
Gel zymography with gelatin as a substrate was performed to
detect and compare MMP-9 activity. Briefly, protein extracts that
contained active MMPs were prepared from the whole brain
(primarily the cortex and hippocampus) of Mmp-9 heterozygotes
and their wt counterparts and were analyzed by gelatin gel
zymography using a previously described method (Lepeta et al.,
2017). The gels were stained with Coomassie Blue. The intensity
of lighter colored bands that corresponded to MMP-9 and
MMP-2 was analyzed using ImageJ software. MMP-9 activity was
determined after normalization to MMP-2 activity.
Statistical Analyses
The behavioral data were analyzed using GraphPad Prism
6.0 software and two-way analysis of variance (ANOVA),
unpaired t-test, and the nonparametric Mann-Whitney U-test.
The data are expressed as mean ± standard error of mean (SEM)
for samples with n > 5.
RESULTS
The present study investigated the effects of low MMP-9
activity on the predisposition to schizophrenia-like symptoms in
mice that were subjected to psychosocial stress. We employed
a milder modification of the resident intruder paradigm to
induce psychosocial stress in mice, that appears to be an
ethologically appropriate social defeat paradigm (Adamcio
et al., 2009). Mmp-9 heterozygous mice were exposed to the
stress procedure; cognitive deficits and negative and positive
FIGURE 2 | Effect of clozapine on negative symptoms. (A) Schematic
diagram of clozapine treatment. (B) Clozapine treatment attenuated the
increase in immobility in stressed Mmp-9 heterozygous mice in the tail
suspension test compared with their non-stressed counterparts and stressed
wt mice. No effects of clozapine were observed in the vehicle-treated group
(individual t-test, p < 0.05). (C) Clozapine ameliorated the differences in
interaction time between stressed and non-stressed wt and heterozygous
mice. Vehicle treatment alone did not exert any effects in stressed
heterozygous mice, which exhibited a significant decrease in interaction time
(individual t-test, p < 0.05) compared with wt mice. wt, wt control mice; Het,
Mmp-9 heterozygous mice. ∗p < 0.05.
schizophrenia symptoms were assessed (Figure 1A). We used
only one test to assess positive symptoms (i.e., MK-801-induced
hyperlocomotion), one test to assess cognitive deficits (i.e., novel
object recognition test), and two tests to evaluate negative
symptoms in Mmp-9 heterozygous mice. We performed these
four tests only to ensure that behavioral testing did not fatigue
the mice.
The tail-suspension test was used to evaluate behavioral
despair (i.e., one characteristic negative symptom of
schizophrenia). Stressed Mmp-9 heterozygotes were immobile
for a significantly longer time (individual t-test, p < 0.05;
two-way ANOVA, F(1,37) = 7.008, df = 1, p < 0.05), compared
with both stressed wt animals and non-stressed heterozygous
littermates (Figure 1B), suggesting a diminished ability of
stressed Mmp-9 heterozygotes to cope with the adverse
conditions. Similarly, in the social interaction test, stressed
Mmp-9 heterozygous mice spent a significantly shorter
time interacting with a conspecific gender-matched mouse
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(individual t-test, p < 0.01; two-way ANOVA, F(1,37) = 8.9555,
df = 1, p < 0.05), compared with both stressed wt mice and
non-stressed Mmp-9 heterozygous mice (Figure 1C), indicating
a reduction of sociability. These results indicate the development
of negative-like symptoms of schizophrenia in Mmp-9
heterozygous mice that were subjected to psychosocial stress.
To evaluate cognitive deficits, the mice underwent the
novel object recognition test, which evaluates spatial learning
and memory. Mmp-9 heterozygous mice exhibited learning
and memory impairments, reflected by a significant decrease
in preference to explore the object in a novel location
(individual t-test, p < 0.05), compared with the familiar
location (Figure 1D). Interestingly, stress did not potentiate this
performance impairment in Mmp-9 heterozygotes.
MK-801 is an NMDA receptor antagonist that produces
positive-like symptoms of schizophrenia in rodents (van
den Buuse, 2010). MK-801-treated Mmp-9 heterozygous mice
exhibited hyper-locomotion (individual t-test, p< 0.05; two-way
ANOVA, F(1,37) = 14.61, df = 1, p < 0.005), compared with their
wt littermates (Figure 1E). These findings are consistent with a
previous report (Lepeta et al., 2017). Notably, stressed wt mice
also exhibited an increase in locomotion, but stress exposure did
not accentuate this effect in Mmp-9 heterozygous mice.
Finally, we analyzed the enzymatic activity of MMP-9 by
gel zymography in all four groups of mice before and after
behavioral testing. As expected, Mmp-9 heterozygous mice
exhibited a two-fold decrease in MMP-9 activity. In stressed
Mmp-9 heterozygotes, MMP-9 activity decreased by more than
70% compared with stressed wt mice (Figure 1F; individual
U-test, p< 0.05; two-way ANOVA, F(1,8) = 13.9, df = 1, p< 0.05).
Typical and atypical antipsychotics have been traditionally
used to treat schizophrenia (Asenjo Lobos et al., 2010). Thus, we
investigated whether the negative-like schizophrenia symptoms
that were observed in stressed Mmp-9 heterozygous mice could
be treated with an antipsychotic. Clozapine is an atypical
antipsychotic that is used to treat patients with schizophrenia. In
the present study, it was administered for 10 days after behavioral
training (Figure 2A). The treatment abolished the increase in
immobility that was observed in stressed heterozygous mice in
the tail suspension test (Figure 2B; individual t-test p > 0.05;
two-way ANOVA F(1,18) = 0.1414, df = 1, p > 0.05). Vehicle
treatment did not exert an effect in stressed heterozygous
mice (Figure 2B; t-test, p < 0.05). Vehicle treatment also
did not alter the reduction of social interaction in stressed
Mmp-9 heterozygous mice (Figure 2C; t-test, p < 0.05).
However, clozapine ameliorated the effect of stress in Mmp-9
heterozygotes, with no significant differences in interaction
time between groups (Figure 2C; individual t-test p > 0.05;
two-way ANOVA F(1,18)= 0.0132, df = 1, p > 0.05). Therefore,
clozapine rescued negative-like symptoms of schizophrenia in
our experimental model.
DISCUSSION
The present study found that psychosocial stress that was
induced in the resident-intruder paradigm and low levels
of MMP-9 were collectively required to evoke negative-like
symptoms of schizophrenia in mice, indicated by: (i) an
increase in immobility in the tail suspension test, reflecting
by a decrease in the ability of stressed heterozygous mice to
cope with the adverse conditions; and (ii) a shorter interaction
time with a gender-matched conspecific mouse, reflecting social
withdrawal. We found no influence of gene × environment
interactions on cognitive deficits or positive-like symptoms
of schizophrenia, which have been previously shown to be
affected by lower MMP-9 activity alone (Vafadari et al.,
2016). Importantly, studies of MMP-9 genetic polymorphisms
in human schizophrenia patients have shown that the gene
variants predisposing to lesser MMP-9 expression confer
higher disease risk (Rybakowski et al., 2009; Lepeta et al.,
2017). The present study showed that stress exacerbated
schizophrenia-like symptoms in mice that had low MMP-9 levels,
thus supporting the hypothesis of the involvement of MMP-9
in schizophrenia and suggesting a possible pharmacological
treatment target.
Schizophrenia can be categorized into deficit and non-deficit
types, based on the occurrence of negative symptoms.
Schizophrenia is considered a deficit type if it meets the
criteria of more than two negative symptoms that are not fully
accounted for by already existing depression and anxiety traits,
effects of drugs, or environmental conditions (Kirkpatrick
et al., 2017). The paradigm that we employed in the present
study induced negative symptoms only in stressed Mmp-9
heterozygous mice and not in wt mice, implying that, specifically,
gene × environment interactions and not environmental
influences alone are necessary for the observed phenotype.
Thus, stressed Mmp-9 heterozygous mice might serve as a useful
model of the deficit type of schizophrenia. However, caution
must be taken when considering the reliability of animal models
of schizophrenia (Powell and Miyakawa, 2006; Nestler and
Hyman, 2010; Young et al., 2010; Jones et al., 2011; Canetta and
Kellendonk, 2018).
The positive symptoms of schizophrenia can be treated to
varying degrees by antipsychotics, but negative and cognitive
symptoms are often resistant to such treatment (Nestler and
Hyman, 2010; Young et al., 2010; Jones et al., 2011). Some
studies, however, have reported that some antipsychotics,
such as clozapine, rescued negative symptoms to some extent
(Brar et al., 1997; Remington et al., 2016; Khan and Zaidi,
2017). Such variable effects have been attributed to the fact
that schizophrenia is a heterogeneous disorder, in which
symptom severity and the treatment response vary greatly
between patients. In the present study, we found that the
endophenotypes exhibited by Mmp-9 heterozygous mice that
were exposed to psychosocial stress, particularly the negative
symptoms, were rescued by clozapine. Thus, treatment with
this drug could be considered in cases of schizophrenia
patients who have specific MMP-9 gene variations. The exact
mechanism of action of clozapine remains to be elucidated-
whether by targeting different pathways that are influenced
by low MMP-9 levels, such as brain-derived neurotrophic
factor (Huang, 2013) and glycogen synthase kinase 3β (Kang
et al., 2004), or by directly affecting dendritic spine formation
(Critchlow et al., 2006; Takaki et al., 2018).
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The utility of mouse or other animal models of schizophrenia
has been debated (Powell and Miyakawa, 2006; Nestler and
Hyman, 2010; Young et al., 2010; Jones et al., 2011; Canetta and
Kellendonk, 2018). Nonetheless, animal models that recapitulate
environmental influences (e.g., stress, drugs, infections, and
socioeconomic status) on clinically identified risk-factor genes
in the development of schizophrenia symptoms, including
cognitive, positive, and negative symptoms, are able to provide
insights into possible gene × environment interactions. This is
important for understanding the pathogenesis of schizophrenia
and for identifying possible molecular targets for future
research (Burrows and Hannan, 2016; Moran et al., 2016;
Misiak et al., 2018).
Despite progress in understanding genetic and environmental
risk factors for schizophrenia, little is known about the
mechanisms of gene × environment interactions (Ayhan
et al., 2016). The present study describes a novel mouse model
of schizophrenia-related gene × environment interactions
that involves the risk gene Mmp-9. Stress further decreased
MMP-9 levels in heterozygous mice, which may be directly
related to the endophenotype of negative symptoms of
schizophrenia. However, further studies are required to
understand whether such effects of environmental factors
(i.e., stress) on Mmp-9 gene expression occur through epistatic
or epigenetic changes or broader signaling alterations. An
interesting line of investigation would be to determine the
ways in which low MMP-9 levels affect such behavioral
changes, such as through aberrant synaptic plasticity (Michaluk
et al., 2011; Vafadari et al., 2016) or neuroinflammation.
Notably, MMP-9 has been reported to be involved in
these phenomena (Müller et al., 2015; Vafadari et al., 2016;
van Kesteren et al., 2017).
In conclusion, the present study validated the association
between MMP-9 and schizophrenia symptoms. Low
brain levels of MMP-9 appear to be a risk factor for
schizophrenia, in which gene × environment interactions
that involve Mmp-9 contribute to the pathophysiology of this
neuropsychiatric disorder.
DATA AVAILABILITY




The animal study was reviewed and approved by Local Ethics
Committee (Permission No. 148/2016 and 507/2018) Animal
Protection Act in Poland, Directive 2010/63/EU.
AUTHOR CONTRIBUTIONS
BV, SM, and LK designed the study. BV and SM performed the
experiments and analyzed the data. SM wrote the manuscript. MS
and LK revised the manuscript. BV, SM, MS, and LK approved
the final version of the manuscript.
FUNDING
This study was supported by ExtraBrain EU FP7 and
BRAINCITY MAB/2018/10. The BRAINCITY project is
performed within the International Research Agendas program
of the Foundation for Polish Science (Fundacja na rzecz Nauki
Polskiej), co-financed by the European Union under the
European Regional Development Fund.
REFERENCES
Adamcio, B., Havemann-Reinecke, U., and Ehrenreich, H. (2009). Chronic
psychosocial stress in the absence of social support induces pathological
pre-pulse inhibition in mice. Behav. Brain Res. 204, 246–249. doi: 10.1016/j.
bbr.2009.05.030
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A.,
et al. (2000). Attenuation of the neuropsychiatric effects of ketamine with
lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate
receptor antagonists. Arch. Gen. Psychiatry 57, 270–276. doi: 10.1001/archpsyc.
57.3.270
Asenjo Lobos, C., Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F.,
Schwarz, S., et al. (2010). Clozapine versus other atypical antipsychotics
for schizophrenia. Cochrane Database Syst. Rev. 11:CD006633.
doi: 10.1002/14651858.CD006633.pub2
Ayhan, Y., McFarland, R., and Pletnikov, M. V. (2016). Animal models of
gene-environment interaction in schizophrenia: a dimensional perspective.
Prog. Neurobiol. 136, 1–27. doi: 10.1016/j.pneurobio.2015.10.002
Brar, J. S., Chengappa, K. N., Parepally, H., Sandman, A. R., Kreinbrook, S. B.,
Sheth, S. A., et al. (1997). The effects of clozapine on negative symptoms
in patients with schizophrenia with minimal positive symptoms. Ann. Clin.
Psychiatry 9, 227–234. doi: 10.3109/10401239709147802
Burrows, E. L., and Hannan, A. J. (2016). Cognitive endophenotypes,
gene-environment interactions and experience-dependent plasticity in animal
models of schizophrenia. Biol. Psychol. 116, 82–89. doi: 10.1016/j.biopsycho.
2015.11.015
Canetta, S., and Kellendonk, C. (2018). Can we use mice to study schizophrenia?
Philos. Trans. R. Soc. Lond. B Biol. Sci. 373:20170032. doi: 10.1098/rstb.2017.
0032
Cirulli, F., Francia, N., Berry, A., Aloe, L., Alleva, E., and Suomi, S. J. (2009). Early
life stress as a risk factor for mental health: role of neurotrophins from rodents
to non-human primates. Neurosci. Biobehav. Rev. 33, 573–585. doi: 10.1016/j.
neubiorev.2008.09.001
Critchlow, H. M., Maycox, P. R., Skepper, J. N., and Krylova, O. (2006).
Clozapine and haloperidol differentially regulate dendritic spine formation and
synaptogenesis in rat hippocampal neurons. Mol. Cell. Neurosci. 32, 356–365.
doi: 10.1016/j.mcn.2006.05.007
Defensor, E. B., Pearson, B. L., Pobbe, R. L. H., Bolivar, V. J., Blanchard, D. C., and
Blanchard, R. J. (2011). A novel social proximity test suggests patterns of social
avoidance and gaze aversion-like behavior in BTBR T+ tf/J mice. Behav. Brain
Res. 217, 302–308. doi: 10.1016/j.bbr.2010.10.033
du Bois, T. M., and Huang, X. F. (2007). Early brain development
disruption from NMDA receptor hypofunction: relevance to
schizophrenia. Brain Res. Rev. 53, 260–270. doi: 10.1016/j.brainresrev.2006.
09.001
Flores, G., Morales-Medina, J. C., and Diaz, A. (2016). Neuronal and brain
morphological changes in animal models of schizophrenia. Behav. Brain Res.
301, 190–203. doi: 10.1016/j.bbr.2015.12.034
Frontiers in Behavioral Neuroscience | www.frontiersin.org 6 August 2019 | Volume 13 | Article 195
Vafadari et al. MMP-9 and Schizophrenia
Gottesman, I. I., and Shields, J. (1967). A polygenic theory of schizophrenia. Proc.
Natl. Acad. Sci. U S A 58, 199–205. doi: 10.1073/pnas.58.1.199
Grayson, B., Leger, M., Piercy, C., Adamson, L., Harte, M., and Neill, J. C.
(2015). Assessment of disease-related cognitive impairments using the novel
object recognition (NOR) task in rodents. Behav. Brain Res. 285, 176–193.
doi: 10.1016/j.bbr.2014.10.025
Haddad, L., Schäfer, A., Streit, F., Lederbogen, F., Grimm, O., Wüst, S.,
et al. (2015). Brain structure correlates of urban upbringing, an
environmental risk factor for schizophrenia. Schizophr. Bull. 41, 115–122.
doi: 10.1093/schbul/sbu072
Hosak, L. (2013). New findings in the genetics of schizophrenia. World
J. Psychiatry 3, 57–61. doi: 10.5498/wjp.v3.i3.57
Hosák, L., and Hosakova, J. (2015). The complex etiology of schizophrenia: general
state of the art. Neuro Endocrinol. Lett. 36, 631–637.
Huang, T. L. (2013). Effects of antipsychotics on the BDNF in schizophrenia. Curr.
Med. Chem. 20, 345–350. doi: 10.2174/092986713804870729
Huntley, G. W. (2012). Synaptic circuit remodelling by matrix metalloproteinases
in health and disease. Nat. Rev. Neurosci. 13, 743–757. doi: 10.1038/nrn3320
Jones, C. A., Watson, D. J. G., and Fone, K. C. F. (2011). Animal models of
schizophrenia. Br. J. Pharmacol. 164, 1162–1194. doi: 10.1111/j.1476-5381.
2011.01386.x
Kang, U. G., Seo, M. S., Roh, M. S., Kim, Y., Yoon, S. C., and Kim, Y. S. (2004). The
effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett. 560,
115–119. doi: 10.1016/s0014-5793(04)00082-1
Kelly, B. D., O’Callaghan, E., Waddington, J. L., Feeney, L., Browne, S., Scully, P. J.,
et al. (2010). Schizophrenia and the city: a review of literature and prospective
study of psychosis and urbanicity in Ireland. Schizophr. Res. 116, 75–89.
doi: 10.1016/j.schres.2009.10.015
Khan, A. H., and Zaidi, S. (2017). Clozapine: improvement of negative symptoms
of schizophrenia. Cureus 9:e1973. doi: 10.7759/cureus.1973
Kirkpatrick, B., Mucci, A., and Galderisi, S. (2017). Primary, enduring
negative symptoms: an update on research. Schizophr. Bull. 43, 730–736.
doi: 10.1093/schbul/sbx064
Lederbogen, F., Haddad, L., and Meyer-Lindenberg, A. (2013). Urban social stress:
risk factor for mental disorders. The case of schizophrenia. Environ. Pollut. 183,
2–6. doi: 10.1016/j.envpol.2013.05.046
Lepeta, K., and Kaczmarek, L. (2015). Matrix metalloproteinase-9 as a novel
player in synaptic plasticity and schizophrenia. Schizophr. Bull. 41, 1003–1009.
doi: 10.1093/schbul/sbv036
Lepeta, K., Purzycka, K. J., Pachulska-Wieczorek, K., Mitjans, M., Begemann, M.,
Vafadari, B., et al. (2017). A normal genetic variation modulates synaptic
MMP-9 protein levels and the severity of schizophrenia symptoms. EMBOMol.
Med. 9, 1100–1116. doi: 10.15252/emmm.201707723
Lewis, G., David, A., Andréassson, S., and Allebeck, P. (1992). Schizophrenia and
city life. Lancet 340, 137–140. doi: 10.1016/0140-6736(92)93213-7
Lewis, D. A., and Lieberman, J. A. (2000). Catching up on schizophrenia:
natural history and neurobiology. Neuron 28, 325–334. doi: 10.1016/S0896-
6273(00)00111-2
Mackay-Sim, A., Féron, F., Eyles, D., Burne, T., and McGrath, J. (2003).
Schizophrenia, vitamin D, and brain development. Int. Rev. Neurobiol. 59,
351–380. doi: 10.1016/S0074-7742(04)59014-1
McGrath, J., Saha, S., Welham, J., El Saadi, O., MacCauley, C., and Chant, D.
(2004). A systematic review of the incidence of schizophrenia: the distribution
of rates and the influence of sex, urbanicity, migrant status and methodology.
BMCMed. 2:13. doi: 10.1186/1741-7015-2-13
McGuffin, P., Tandon, K., and Corsico, A. (2003). Linkage and association studies
of schizophrenia. Curr. Psychiatry Rep. 5, 121–127. doi: 10.1007/s11920-003-
0028-y
Michaluk, P., Wawrzyniak, M., Alot, P., Szczot, M., Wyrembek, P., Mercik, K.,
et al. (2011). Influence of matrix metalloproteinase MMP-9 on dendritic spine
morphology. J. Cell Sci. 124, 3369–3380. doi: 10.1242/jcs.090852
Misiak, B., Stramecki, F., Gaweda, Ł., Prochwicz, K., S≤asiadek, M. M.,
Moustafa, A. A., et al. (2018). Interactions between variation in candidate
genes and environmental factors in the etiology of schizophrenia and
bipolar disorder: a systematic review. Mol. Neurobiol. 55, 5075–5100.
doi: 10.1007/s12035-017-0708-y
Mizoguchi, H., Ibi, D., Takuma, K., Toth, E., Sato, J., Itohara, S., et al.
(2010). Alterations of emotional and cognitive behaviors in matrix
metallo-proteinase-2 and -9-deficient mice. Open Behav. Sci. J. 4, 19–22.
doi: 10.2174/1874230001004010019
Moran, P., Stokes, J., Marr, J., Bock, G., Desbonnet, L., Waddington, J.,
et al. (2016). Gene × environment interactions in schizophrenia: evidence
from genetic mouse models. Neural Plast. 2016:2173748. doi: 10.1155/2016/
2173748
Morgan, C., Burns, T., Fitzpatrick, R., Pinfold, V., and Priebe, S. (2007). Social
exclusion and mental health: conceptual and methodological review. Br.
J. Psychiatry 191, 477–483. doi: 10.1192/bjp.bp.106.034942
Moyer, C. E., Shelton, M. A., and Sweet, R. A. (2015). Dendritic spine alterations
in schizophrenia. Neurosci. Lett. 601, 46–53. doi: 10.1016/j.neulet.2014.
11.042
Müller, N., Weidinger, E., Leitner, B., and Schwarz, M. J. (2015). The role of
inflammation in schizophrenia. Front. Neurosci. 9:372. doi: 10.3389/fnins.2015.
00372
Nestler, E. J., and Hyman, S. E. (2010). Animal models of neuropsychiatric
disorders. Nat. Neurosci. 13, 1161–1169. doi: 10.1038/nn.2647
Olney, J. W., Newcomer, J. W., and Farber, N. B. (1999). NMDA receptor
hypofunction model of schizophrenia. J. Psychiatr. Res. 33, 523–533.
doi: 10.1016/S0022-3956(99)00029-1
Owen, M. J., Craddock, N., and O’Donovan, M. C. (2005). Schizophrenia: genes at
last? Trends Genet. 21, 518–525. doi: 10.1016/j.tig.2005.06.011
Penzes, P., Cahill, M. E., Jones, K. A., Vanleeuwen, J. E., and Woolfrey, K. M.
(2011). Dendritic spine pathology in neuropsychiatric disorders. Nat. Neurosci.
14, 285–293. doi: 10.1038/nn.2741
Porsolt, R. D., McArthur, R. A., and Lenègre, A. (1993). ‘‘Psychotropic screening
procedures,’’ in Methods in Behavioral Pharmacology (Vol. 10), ed. F. van
Haaren (New York, NY: Elsevier), 23–51.
Powell, C. M., and Miyakawa, T. (2006). Schizophrenia-relevant behavioral testing
in rodent models: a uniquely human disorder? Biol. Psychiatry 59, 1198–1207.
doi: 10.1016/j.biopsych.2006.05.008
Pryce, C. R., and Fuchs, E. (2016). Chronic psychosocial stressors in adulthood:
studies in mice, rats and tree shrews. Neurobiol. Stress 6, 94–103. doi: 10.1016/j.
ynstr.2016.10.001
Remington, G., Foussias, G., Fervaha, G., Agid, O., Takeuchi, H., Lee, J., et al.
(2016). Treating negative symptoms in schizophrenia: an update. Curr. Treat.
Options Psychiatry 3, 133–150. doi: 10.1007/s40501-016-0075-8
Rybakowski, J. K., Skibinska, M., Kapelski, P., Kaczmarek, L., and Hauser, J.
(2009). Functional polymorphism of the matrix metalloproteinase-9 (MMP-9)
gene in schizophrenia. Schizophr. Res. 109, 90–93. doi: 10.1016/j.schres.2009.
02.005
Saha, S., Chant, D., Welham, J., and McGrath, J. (2005). A systematic review of
the prevalence of schizophrenia. PLoS Med. 2:e141. doi: 10.1371/journal.pmed.
0020141
Sanders, A. R., Duan, J., Levinson, D. F., Shi, J., He, D., Hou, C.,
et al. (2008). No significant association of 14 candidate genes with
schizophrenia in a large European ancestry sample: implications for
psychiatric genetics.Am. J. Psychiatry 165, 497–506. doi: 10.1176/appi.ajp.2007.
07101573
Schmitt, A., Malchow, B., Hasan, A., and Falkai, P. (2014). The impact of
environmental factors in severe psychiatric disorders. Front. Neurosci. 8:19.
doi: 10.3389/fnins.2014.00019
Stuchlik, A., and Sumiyoshi, T. (2014). Cognitive deficits in schizophrenia
and other neuropsychiatric disorders: convergence of preclinical and
clinical evidence. Front. Behav. Neurosci. 8:444. doi: 10.3389/fnbeh.2014.
00444
Szepesi, Z., Hosy, E., Ruszczycki, B., Bijata, M., Pyskaty, M., Bikbaev, A., et al.
(2014). Synaptically released matrix metalloproteinase activity in control of
structural plasticity and the cell surface distribution of GluA1-AMPA receptors.
PLoS One 9:e98274. doi: 10.1371/journal.pone.0098274
Takaki, M., Kodama, M., Mizuki, Y., Kawai, H., Yoshimura, B., Kishimoto, M.,
et al. (2018). Effects of the antipsychotics haloperidol, clozapine, and
aripiprazole on the dendritic spine. Eur. Neuropsychopharmacol. 28, 610–619.
doi: 10.1016/j.euroneuro.2018.03.004
Trotta, A., Di Forti, M., Mondelli, V., Dazzan, P., Pariante, C., David, A., et al.
(2013). Prevalence of bullying victimisation amongst first-episode psychosis
patients and unaffected controls. Schizophr. Res. 150, 169–175. doi: 10.1016/j.
schres.2013.07.001
Frontiers in Behavioral Neuroscience | www.frontiersin.org 7 August 2019 | Volume 13 | Article 195
Vafadari et al. MMP-9 and Schizophrenia
Tsuang, M. (2000). Schizophrenia: genes and environment. Biol. Psychiatry 47,
210–220. doi: 10.1016/s0006-3223(99)00289-9
Vafadari, B., Salamian, A., and Kaczmarek, L. (2016). MMP-9 in translation:
from molecule to brain physiology, pathology, and therapy. J. Neurochem. 139,
91–114. doi: 10.1111/jnc.13415
van den Buuse, M. (2010). Modeling the positive symptoms of schizophrenia in
genetically modified mice: pharmacology and methodology aspects. Schizophr.
Bull. 36, 246–270. doi: 10.1093/schbul/sbp132
van Kesteren, C. F., Gremmels, H., de Witte, L. D., Hol, E. M., Van Gool, A. R.,
Falkai, P. G., et al. (2017). Immune involvement in the pathogenesis of
schizophrenia: a meta-analysis on postmortem brain studies. Transl. Psychiatry
7:e1075. doi: 10.1038/tp.2017.4
van Os, J., Kenis, G., and Rutten, B. P. F. (2010). The environment and
schizophrenia. Nature 468, 203–212. doi: 10.1038/nature09563
Vogel-Ciernia, A., and Wood, M. A. (2014). Examining object location and
object recognition memory in mice. Curr. Protoc. Neurosci. 69, 8.31.1–8.31.17.
doi: 10.1002/0471142301.ns0831s69
Wilczynski, G. M., Konopacki, F. A., Wilczek, E., Lasiecka, Z., Gorlewicz, A.,
Michaluk, P., et al. (2008). Important role of matrix metalloproteinase-9 in
epileptogenesis. J. Cell Biol. 180, 1021–1035. doi: 10.1083/jcb.200708213
Young, J. W., Zhou, X., and Geyer, M. A. (2010). Animal models of schizophrenia.
Curr. Top. Behav. Neurosci. 4, 391–433. doi: 10.1007/7854_2010_62
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Vafadari, Mitra, Stefaniuk and Kaczmarek. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Behavioral Neuroscience | www.frontiersin.org 8 August 2019 | Volume 13 | Article 195
